Patient demographics
| NI-RADS Score | No. of Cases | Sex | Mean Age (yr) | Smoking History | Subsite of Primary Tumor | T-Stage | HPV Status | Recurrences |
|---|---|---|---|---|---|---|---|---|
| NI-RADS 2 | 197 | 62 F 135 M | 64 | 75.6% (149) | Oral cavity (73) Oropharynx (48) Hypopharynx (18) Larynx (49) Nasopharynx (7) Unknown (2) | T1 (35) T2 (35) T3 (32) T4 (10) T4a (56) T4b (9) Unknown (20) | 32 (+) 9 (−) 2 Unknown | Total: 23 (8 clinically occult recurrences) 17 Biopsy-proved 6 Imaging and clinical progression |
| NI-RADS 3 | 58 | 17 F 41 M | 63 | 75.9% (44) | Oral cavity (28) Oropharynx (17) Hypopharynx (4) Larynx (8) Nasopharynx (1) | T1 (4) T2 (14) T3 (5) T4 (8) T4a (17) T4b (6) Unknown (4) | 0 (+) 1 (−) 1 Unknown | Total: 36 (13 clinically occult recurrences) 28 Biopsy-proved 8 Imaging and clinical progression |
| NI-RADS 4 | 38 | 10 F 28 M | 63.4 | 71.1% (27) | Oral cavity (8) Oropharynx (16) Hypopharynx (2) Larynx (11) Nasopharynx (1) | T1 (4) T2 (7) T3 (6) T4 (1) T4a (15) T4b (1) Unknown (4) | 8 (+) 4 (−) 1 Unknown | All patients excluded 33 Biopsy-proved recurrence 5 Imaging and clinical progression |
| Total (276 CECT, 17 PET/CECT) | 293 | 89 F 204 M | 63.5 | 75.1% (220) | Oral cavity (109) Oropharynx (81) Hypopharynx (24) Larynx (68) Nasopharynx (9) Unknown (2) | T1 (43) T2 (56) T3 (43) T4 (19) T4a (88) T4b (16) Unknown (28) | 40 (+) 14 (−) 4 Unknown | 59 NI-RADS 2 and 3 38 NI-RADS 4 (excluded) |